01—Abstract
Summary
Summary of the 10-K filed February 17, 2012. Cited figures are marked; the original filing is the authoritative source.
IDEXX Laboratories' FY2011 Form 10-K shows a company that grew revenue 10.4% to $1.219 billiona, with net income attributable to stockholders of $161.8 million, or $2.78 diluted EPS, up from $2.37 in 2010.
Growth was broad-based: Companion Animal Group (CAG) revenue rose 10.4% to $999.7 millionb, led by reference laboratory services (+13.4%) and instruments and consumables (+11.4%), while organic growth was 7.8% after adjusting for currency (+2.4%) and acquisitions (+0.2%). Gross margin expanded to 53.0% from 52.4%, and operating margin improved to 19.4% from 18.5%, driven by manufacturing cost improvements and higher-margin mix. Cash generation was strong, with operating cash flow of $220.7 million, but the balance sheet became more levered.
The company spent $255.5 millionc repurchasing 3.4 million shares, and borrowings under its $300 million revolving Credit Facility rose to $243.0 million, which is classified as a current liability. Working capital fell to $87.3 million from $175.5 million, and total debt increased to $246.4 million from $133.3 million. The company also made acquisitions, most notably the RADIL bioresearch laboratory for $43.0 million, and plans a 2012 capital expenditure budget of about $60 million.
Key risks include a pending FTC investigation into companion animal sales practices, which the company believes is nearing a conclusion and could lead to prospective remedies but no financial penalties; customer concentration, with Butler Schein accounting for 9%d of revenue; dependence on sole-source suppliers, including Ortho for chemistry slides; and exposure to a strong U.S. dollar, with about 43% of revenue generated internationally. The company has never paid a cash dividend.
02—Key points
Key Highlights
- Revenue grew 10.4% to $1,218.7 million, with 7.8% organic growth; CAG reference laboratory services grew 13.4% and instruments and consumables grew 11.4%.
- Diluted EPS rose to $2.78 from $2.37 (+17%), and net income attributable to IDEXX reached $161.8 million.
- Gross margin improved to 53.0% from 52.4%, and operating margin improved to 19.4% from 18.5%.
- Operating cash flow was $220.7 million, up from $178.8 million.
- The company repurchased $255.5 million of stock (3.4 million shares at an average of $74.74), and the remaining authorization is 4.39 million shares.
- Total debt rose to $246.4 million from $133.3 million, and Credit Facility borrowings of $243.0 million are classified as current, leaving working capital at $87.3 million versus $175.5 million a year earlier.
- Key risks include the FTC investigation into companion animal sales practices, customer concentration (Butler Schein at 9% of revenue), sole-source supplier dependence, and U.S. dollar strength (43% of revenue is international).
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2011, IDEXX Laboratories kept $0.13.
- Revenue$1.22B100.0%
- Cost of revenue−$572.2M47.0%
- Gross profit$646.5M53.0%
- Operating costs−$410.3M33.7%
- Operating income$236.2M19.4%
- Interest, other & tax−$74.4M6.1%
- Net income$161.8M13.3%
Where FY2011 revenue went
$1.22B- Cost of revenue: $572.2M, 47% of revenue
- Other operating costs: $334.2M, 27% of revenue
- Net income: $161.8M, 13% of revenue
- R&D: $76.0M, 6.2% of revenue
- Interest, other & tax: $74.4M, 6.1% of revenue
Kept 13% as net income
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2011filed February 17, 2012Financial Statements
FY2011 against FY2010
| Line item | FY2011FY2010 | Change |
|---|---|---|
| Revenue | $1.22B$1.10B | +10.4% |
| Cost of Revenue | $572.18M$524.77M | +9.0% |
| Gross Profit | $646.51M$578.62M | +11.7% |
| R&D Expenses | $76.04M$68.60M | +10.9% |
| Operating Income | $236.22M$203.88M | +15.9% |
| Interest Expense | $3.55M$2.42M | +46.9% |
| Net Income | $161.79M$141.28M | +14.5% |
| EPS (Basic) | $1.43$1.23 | +16.3% |
| EPS (Diluted) | $1.39$1.19 | +17.3% |
| Shares Outstanding (Basic) | 113.58M115.43M | −1.6% |
| Shares Outstanding (Diluted) | 116.43M119.12M | −2.3% |
05—Questions
Frequently Asked Questions
How did IDEXX perform financially in 2011?
IDEXX grew total revenue 10.4% to $1.22 billion, with 7.8% organic growth after excluding currency and acquisition effects. Income from operations rose 15.9% to $236.2 million, and diluted EPS increased to $2.78 from $2.37.
What drove growth in the Companion Animal Group?
Reference laboratory diagnostic and consulting services grew 13.4% on higher testing volumes from new customers and price increases. Instruments and consumables grew 11.4%, driven by Catalyst Dx and ProCyte Dx analyzers, which offset declining VetTest and VetAutoread placements as customers upgraded.
Is IDEXX's balance sheet becoming more leveraged?
Yes. Total debt rose to $246.4 million from $133.3 million, mainly because the company borrowed under its revolving Credit Facility to fund $255.5 million in share repurchases and about $47 million in acquisitions. Management states that the leverage covenant limit is 3-to-1 and that the company was in compliance at year-end. The company also expects interest expense to rise in 2012 because of the higher credit spread.
What are the main regulatory and legal risks?
The FTC is investigating whether IDEXX's companion animal pricing and marketing practices violated antitrust law. The company believes the FTC is nearing a decision on whether to file an administrative complaint, which could seek only prospective remedies and no financial penalties. Management believes its practices are lawful and has not accrued a loss contingency. A separate UK OFT investigation was closed in November 2011 with no action taken.
Does IDEXX pay dividends or return capital to shareholders?
IDEXX pays no cash dividend and has no present intention to do so. Instead, it returns capital through share repurchases. In 2011 it bought back 3.4 million shares for $255.5 million, and 4.39 million shares remain under the 48 million-share authorization.
06—Continue